SomnusNooze e-newsletter
News, stories and updates from the world of sleep
SomnusNooze topics: HF news
In Case You Missed It! – July 2018
This month, we begin a new SomnusNooze series entitled “In Case You Missed It!” This series will highlight topics relating to sleep disorders that have been in the news and/or in our recent social media posts. Check here each month to make sure that... read >
Board Member Amy Haraden Speaks About Living with IH at SLEEP2 Conference
On June 3, 2017, Board Member Amy Haraden participated in a Patient Panel at the SLEEP2 (PCORI) Conference organized by Project Sleep. SLEEP2 is a project co-led by the University of Arizona, the Sleep Research Network, and Project Sleep and is funded... read >
Arise Clinical Trial
CLINICAL TRIAL ENROLLING PATIENTS WITH IDIOPATHIC HYPERSOMNIA AND NARCOLEPSY TYPE 2 Balance Therapeutics is evaluating an investigational new drug BTD-001, to treat excessive daytime sleepiness in individuals diagnosed with idiopathic hypersomnia... read >
Dr. Lynn Marie Trotti Presents at AAN Annual Meeting
AAN is the American Academy of Neurology, and the meeting was held in Boston, MA, April 22-28, 2017. The AAN Annual Meeting is the world's largest gathering of neurologists, bringing together more than 10,000 neurology professionals across the globe to... read >
Let Sleep Researchers Know What’s Important to YOU
HF urges the entire hypersomnia community, including people with IH, people with narcolepsy, all supporters and healthcare professionals, to take a short survey prepared by Project Sleep in partnership with the University of Arizona "to capture... read >
What’s New in the Diagnosis and Treatment of Hypersomnia in 2016?
Rather than writing our own article for this week’s edition of SomnusNooze, we are bringing you information from Dr. David Cunnington in Melbourne, Australia. Dr. Cunnington has agreed to share with us a recent post from his website (sleephub.com.au)... read >
EMA Recommends Approval of Pitolisant for the Treatment of Narcolepsy
On November 20, 2015, the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended that Bioprojet Pharma's drug pitolisant (Wakix) be approved for the treatment of narcolepsy with or without cataplexy. In... read >
The First Multi-Site Clinical Trial for IH and Type 2 Narcolepsy in the US Is Underway
ARISE 201 is the first double-blind, placebo-controlled, crossover, multicenter study of a drug (BTD-001) for the treatment of idiopathic hypersomnia (IH) and type 2 narcolepsy (T2N) in adults. More than 20 study sites throughout the United States are... read >
BUNIHPPS – An Online Research Survey for Narcolepsy & IH Patients
https://www.hypersomniafoundation.org/research-study/bunihpps/ Dear IH Community members: A research team at Boston University has developed BUNIHPPS -- a survey research study for patients with narcolepsy and idiopathic hypersomnia. Also called the... read >
Research Opportunity
Victoria University, Melbourne Australia is commencing a study about the general health and well-being of people within three groups. One group will be those with both narcolepsy and cataplexy. Cataplexy is a sudden loss of muscle tone, often triggered... read >